Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00367601 · ClinicalTrials.gov registry record · Phase 2
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Nasser Hanna, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00367601 is a Phase 2 study that has completed, run by Nasser Hanna, M.D.. The registered enrollment target is 25 participants.
The verdict
NCT00367601, a Phase 2 study, has completed, sponsored by Nasser Hanna, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The strategy for combining therapeutic agents in cancer treatments has been successful in multiple tumor types, including NSCLC. Erlotinib and bevacizumab target different pathways involved in tumor growth. Nonclinical studies have demonstrated that the combination of bevacizumab and erlotinib results in greater efficacy than either agent alone. Furthermore, because there is little to no overlap in toxicity profile between the two agents, the combination is expected to be well tolerated and may provide even greater benefit for patients who are unable to receive cytotoxic therapy.
Interventions
- DRUG Bevacizumab
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00367601
The ClinicalTrials.gov registry entry for NCT00367601 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nasser Hanna, M.D., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00367601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00367601 about?
NCT00367601 is a clinical study titled "Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer". The strategy for combining therapeutic agents in cancer treatments has been successful in multiple tumor types, including NSCLC. Erlotinib and bevacizumab target different pathways involved in tumor growth. Nonclinical studies have demonstrated that the combination of bevacizumab and erlotinib resul...
What is the current status of trial NCT00367601?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00367601?
The interventions under investigation include: Bevacizumab (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00367601?
This trial is sponsored by Nasser Hanna, M.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.